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Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is mainly characterized by the selective
and progressive loss of dopaminergic neurons, accompanied by locomotor defects. Although most PD cases are sporadic, several
genes are associated with rare familial forms of the disease. Analyses of their function have provided important insights into the
disease process, demonstrating that three types of cellular defects are mainly involved in the formation and/or progression of PD:
abnormal protein aggregation, oxidative damage, and mitochondrial dysfunction. These studies have been mainly performed in
PD models created in mice, fruit ﬂies, and worms. Among them, Drosophila has emerged as a very valuable model organism in
the study of either toxin-induced or genetically linked PD. Indeed, many of the existing ﬂy PD models exhibit key features of the
disease and have been instrumental to discover pathways relevant for PD pathogenesis, which could facilitate the development of
therapeutic strategies.
1.Introduction
Parkinson’s disease (PD) is the second most common
neurodegenerative disorder aﬀecting more than 1% of the
population over age 60. Clinically, it is characterized by
locomotor defectssuch as muscle rigidity, bradykinesia, pos-
tural instability, and tremor. The principal neuropathology
that gives rise to these motor defects is the progressive
and selective loss of dopaminergic (DA) neurons in the
Substantia nigra pars compacta, which causes a deﬁciency
of brain dopamine content. Another pathological hallmark
of this disorder is the presence of cytoplasmic inclusions in
the surviving DA neurons called Lewy bodies (LBs), which
are mainly composed of α-Synuclein and ubiquitin among
o t h e rp r o t e i n s[ 1, 2]. However, it has been shown that such
structures are not present in some genetic forms of PD.
Although the majority of PD cases are sporadic and
are probably caused by a combination of risk factors like
the aging process, genetic propensity, and environmental
exposures, few environmental triggers have so far been
identiﬁed. Weak associations between PD and exposure to
environmental toxins or herbicides and pesticides have been
reported [2], and several toxin-induced PD models have
been developed [3]. However, epidemiological studies have
also demonstrated the contribution of genetic factors in
the pathogenesis of PD. Indeed, during the last decade,
several loci whose mutations are causative of rare familial
forms of the disease have been identiﬁed, which account for
5%–10% of all PD cases. These genes include α-synuclein,
parkin, ubiquitin C-Terminal hydrolase-1 (UCHL-1), DJ-1,
phosphatase and tensin homolog (PTEN)-induced kinase 1
(PINK1), leucine-rich repeat kinase 2 (LRRK2), Omi/HtrA2,
ATP13A2,and glucocerebrosidase (GBA)[4–14]. However, it
is noteworthy to mention that the relevance of some of them
to PD is currently under debate [15]. Despite this, studies
of the function of PD-linked genes have provided important
insights into PD pathogenesis and have demonstrated that
three types of cellular defects are mainly involved in the
formation and/or progression of the disease: abnormal
protein aggregation, oxidative damage, and mitochondrial
dysfunction [16]. Due to the limitations of human genetic
analysis, most of these studies have been performed in2 Parkinson’s Disease
model organisms, including mice, fruit ﬂies, and worms as
well as in cell culture. Indeed, there are currently many
cellular and animal models of PD either genetic or toxin-
based. Cellular models can be easily used for molecular,
biochemical, and pharmacological approaches, but they can
lead to misinterpretation and artefacts. In contrast, animal
models allow studying a cellular process in the context of
a whole organism and are thus more reliable. Despite this, it
is also remarkable that none of the existing PD animal mod-
els recapitulate all PD symptoms, including those developed
in mice [17].
In such a scenario, the fruit ﬂy Drosophila has emerged
as a valuable model for studying mechanisms of human
neurodegenerative diseases, including PD. Although fruit
ﬂies seem to be completely unrelated to humans, fundamen-
tal cellular processes as well as many genes and signalling
pathways are conserved between both organisms. Moreover,
most of the genes implicated in familial forms of the disease
have at least one ﬂy homolog [18]. In addition, ﬂies are
capable of performing complex motor behaviours such as
walking, climbing, and ﬂying and their brain is complex
enough to make these behaviours relevant to humans. The
availability of very potent genetic tools that are impractical
in mammals, their rapid growth and reproduction, and the
fact that it is cheap and easy to maintain in the laboratory
are features that make Drosophila an ideal model system to
addressnovelbiologicalquestionsincludingthoserelevantto
human health [19–21]. Indeed, studies of genes involved in
familial PDaswell asthedevelopmentoftoxin-based models
of PD in Drosophila have made signiﬁcant contributions to
our understanding of the disease [15, 22, 23]. Here, we have
attempted to provide a comprehensive review on existing
Drosophila models of PD, which have revealed valuable
insights into potential pathogenic mechanisms and have
been used to target modiﬁers of PD pathology by genetic or
pharmacological interference.
2.Toxin-InducedModelsofPD inDrosophila
As indicated above, familial PD cases are extremely rare,
w h i c hs u g g e s t st h a te n v i r o n m e n t a lf a c t o r so rg e n e -
environment interactions play a predominant role in
the development of sporadic PD. For that reason, several
studieshavebeenperformed tomodel PD-associated neuron
loss by neurotoxin intoxication in animals, the most popular
parkinsonian neurotoxins being 6-hydroxydopamine (6-
OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP), rotenone, and paraquat [3, 24]. In general,
toxin-induced PD models do not recapitulate the process
of progressive neuron loss and the protein aggregation in
LBs, due to the acute nature of the neurotoxin treatment
[15], but they have been useful to support the notion
that alterations in mitochondrial biology are essential for
the development of PD [25]. Indeed, mitochondria are
central to the actions of the above-mentioned toxins, which
preferentially injure DA neurons. In Drosophila, several
studies have shown that pharmacological treatment could
be used to model sporadic PD. First, chronic exposure to
the pesticide rotenone, a mitochondrial complex I inhibitor,
recapitulated key aspects of sporadic PD in Drosophila since
it resulted in neurodegenerative and behavioural defects
[26]. Indeed, rotenote-treated ﬂies showed dose-dependent
motor deﬁcits quantiﬁed by a negative geotaxis test, which
is commonly used to perform locomotor ability analyses in
Drosophila, as well as selective loss of DA neurons in all the
brain clusters. In a diﬀerent study, paraquat exposure caused
reduced lifespan in ﬂies as well as movement disorders
such as resting tremors, bradykinesia, rotational behaviours,
and postural instability, which mirror PD symptoms.
These complex set of locomotor phenotypes were overall
quantiﬁed by a negative geotaxis test. The authors also
demonstrated that such phenotypes were caused by selective
loss of DA neuron clusters [27]. Thus, both studies robustly
modelled environmental toxin-induced PD in Drosophila
and provide useful tools for studying the mechanism of
DA neurodegeneration. Drosophila models of MPTP- or
6-OHDA-induced Parkinsonism have not been established
so far.
3.DrosophilaModelsof FamilialPD
The discovery of several genes aﬀected in familial forms of
PD has provided a new tool for PD modelling. Indeed,
many PD animal models have been generated based on gene
mutationsthat are linkedtothedisease includingDrosophila
[15, 17, 19–21, 23, 28]. Although Drosophila PD models
cannot recapitulate fully the phenotypic and pathologic
features of human PD patients, loss of DA neurons and
locomotor defects have been observed in most of them.
Moreover, they have oﬀered the advantage of identifying
evolutionary conserved pathways and cellular processes
relevant to PD pathogenesis.
Diﬀerent approaches have been used to generate PD
models in Drosophila. In some cases, no Drosophila
orthologs of a speciﬁc PD-linked gene do exist. Then, the
model is generated by misexpression of the human gene
either in its wild-type or mutant form, which is usually
achieved by using the GAL4/UAS system [29]. Widely used
in Drosophila genetic studies, this system allows time-
and tissue-speciﬁc misexpression of any gene of interest
in ﬂies. Alternatively, when an ortholog of the human
gene is present in the Drosophila genome, loss-of-function
(LOF)/knockdown alleles of the gene can be generated by
diﬀerentgenetictechniques,includingRNAi.Moreover, mis-
expression of thecorresponding gene can also be carried out.
Ingeneral,misexpression ofeitherhumanorDrosophilaPD-
related genes is performed when the PD forms associated to
them have a dominant inheritance. In that case, Drosophila
PD models are established using GAL4 drivers speciﬁc of
the nervous system or of other tissues, like eyes or wings,
in which a possible phenotype can be easily identiﬁed
without aﬀecting ﬂy survival. LOF/knockdown alleles are
phenotypically characterized when the PD forms associated
to the corresponding genes have a recessive inheritance. By
using any of these strategies, several Drosophila PD models
based on diﬀerent PD-linked genes have been generated.
Examples of phenotypes obtained in these models are shown
in Figure 1.Parkinson’s Disease 3
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Figure 1: Representative phenotypes found in diﬀerent Drosophila PD models. (a)–(d) DA neuron loss detected in Drosophila adult brains
by immunostainings with anti-TH antibody, which speciﬁcally recognizes these neurons, in paraﬃn sections (a, b) or whole-mount brains
(c, d). A reduction in the number of DA neurons is observed in both Ddc-GAL4/DJ-1α RNAi (b) [50]a n dDdc-GAL4/UAS-α-Synuclein (d)
[51]b ra i n sw h e nc o mp a r e dt oa g e - ma t c h e dDdc-GAL4/+controls (a,c).(e)–(j) Examplesofphenotypes observedin parkin LOF mutants (f,
h, j) compared to controls (e, g, i).They include downturned wings (f),muscledegeneration (h), and abnormalmitochondrialmorphology
(j)[52].(k)Premature lossofclimbingabilityin transgenicﬂies expressing wild-type, A30P,andA53Tmutantformsofα-Synuclein [34].(l)
Reduced lifespan of DJ-1β mutants compared to y, w control ﬂies cultured under the same conditions. (m) Elevated sensitivity to paraquat
stress in DJ-1α and DJ-1β mutant ﬂies, represented by calculating the percentage of dead ﬂies after feeding 15mM for 18h [53]. (n)–(o)
Quantiﬁcation of oxidative stress levels in 1-2-day-old DJ-1β mutants and age-matched y, w control ﬂies. DJ-1β mutants show an increase
in lipid peroxidation (LPO) product malondialdehyde (MDA) (n). Catalase(CAT) enzymatic activity is also increased (o) [54].
3.1.α-Synuclein. Itencodesasmall proteinwhosephysiolog-
ical function remains to be elucidated. However, mutations
in the α-synuclein gene such as amino acid substitutions
(A30P, E46K, and A53T), duplications, and triplications are
causative of dominantly inherited forms of PD [4, 30–32].
Interestingly, α-Synucleinisoneofthemajorstructuralcom-
ponents of LBs [33]. The ﬁrst ﬂy PD model was generated
by overexpression of transgenes encoding either wild-type
or mutant forms of human α-Synuclein in all Drosophila
neurons since the Drosophila genome does not contain
ac l e a rα-synuclein homolog [34]. This resulted in an age-
dependent and selective (complete or near complete) loss of
DA neurons in the dorsomedial clusters (DMC) of the brain
and formation of ﬁbrillar α-Synuclein inclusions as well as
a progressive loss of climbing ability, thus reproducing key
PD features. Although several discrepancies regarding DA
neuron loss upon α-synuclein overexpression were reported
in subsequent studies [35, 36], associated to the diﬀerent
sensitivity of the methods used for DA neuron detection,
recent analyses have conﬁrmed that phenotype [37–39].
DA neurons were initially detected in paraﬃn-embedded
brain sections stained with a speciﬁc marker (anti-Tyrosine
hydroxylase (TH) antibody) (Figures 1(a) and 1(b)), but
subsequent analyses were performed in whole-mount brain4 Parkinson’s Disease
preparationsbyconfocalmicroscopy(Figures1(c)and1(d)).
It has been proposed that while in paraﬃn-embedded
sections only healthy DA neurons can be detected, some
ﬂuorescence is still observed in degenerating DA neurons. In
any case, this ﬂy model has been instrumental to decipher
the neuropathological eﬀects of the α-Synuclein protein
as well as the regulation of aggregate formation. It has
beendemonstrated that inhibitionofendoplasmic reticulum
(ER)-Golgi traﬃcking and oxidative stress induction are
major components of α-Synuclein-dependent toxicity [37–
40]. Moreover, quantitative proteome analyses performed
either on wild-type, A30P, or A53Tα-Synuclein overexpress-
ing ﬂies at diﬀerent disease stages revealed that deregulated
proteins are primarily associated with membrane, endoplas-
mic reticulum, actin cytoskeleton, mitochondria, ribosome,
cellular metabolism, and signalling [41–44]. Regarding
α-Synuclein aggregation, overexpression of truncated forms
of α-Synuclein in ﬂies led to discover a central hydrophobic
region of the protein which is essential for its aggrega-
tion as well as sequences C-terminal to residue 120 that
have a more moderate role in inﬂuencing both aggrega-
tion and toxicity [45]. Moreover, several posttranslational
modiﬁcations seem to regulate aggregation and toxicity of
α-Synuclein. While phosphorylation of this protein at serine
129 is prominent in PD and inﬂuences α-Synuclein DA
toxicity [46], phosphorylation at tyrosine 125 inhibits toxic
oligomer formation and decreases with aging [47, 48]. These
datasuggestthatα-SynucleinneurotoxicityinPDandrelated
synucleinopathies may result from an imbalance between
diﬀerentC-phosphorylationeventsontheprotein,regardless
of the impact of such modiﬁcations on the normal function
of α-Synuclein [48, 49].
3.2. Parkin. Mutations in the parkin gene were originally
identiﬁed in families with autosomal recessive juvenile
Parkinsonism (ARJP) [5]. It is the second most commonly
aﬀected PD gene and encodes a ubiquitin ligase associated
withproteasomaldegradation[55–57].Sincethisgeneisw ell
conserved in Drosophila, several groups generated parkin
nullmutantsinordertounderstanditsbiologicalroleinﬂies.
Although these mutants are viable, loss of Drosophila parkin
function results in mitochondrial defects, degeneration of
indirect ﬂight muscles, hypersensitivity to oxidative and
environmental stress, male sterility, reduced lifespan, partial
lethality, and severe defects in both ﬂight and climbing
abilities [52, 58, 59]. It seems that oxidative stress, perhaps
as a consequence of mitochondrial dysfunction, is a major
determinant of those phenotypes [52, 60, 61]. Further-
more, parkin seems to be essential for the morphology,
function, and integrity of several clusters of DA neurons
in the Drosophila brain [59, 62]. Thus, ﬂy parkin mutants
recapitulate some key features of ARJP, suggesting that the
mechanisms of DA neurodegeneration in mutant ﬂies could
resemble those underlying DA neuron loss in ARJP. It was
proposed that loss of parkin function may lead to accumu-
lation of one or several of its numerous substrates in the
braintherebyresultinginERstress,whichinturnmayleadto
DA neuron death [28]. Regarding this, there are two studies
in Drosophila which suggest that abnormal accumulation of
Parkin substrates in Parkin-deﬁcient DA neurons could be
one ofthe causesofneurodegeneration.First, overexpression
of human Parkin-associated endothelin-likereceptor (PAEL-
R), a Parkin substrate protein [63], in ﬂies induces DA
neuron loss in the DMC [64]. However, no Drosophila
ortholog of this Parkin substrate has been described. We
also demonstrated that targeted expression of Septin 4, the
Drosophila ortholog of the human Parkin substrate CDCrel-
1[ 57], in DA neurons also causes age-dependent disruption
ofDAintegrityintheDMC[65].Sincethisneurotoxicitywas
dependent on parkin function and both proteins were able
to interact in vitro, our results suggest that Septin4 could be
a genuine substrate of Parkin in Drosophila [65]. This
was the ﬁrst study showing that accumulation of a Parkin
substrate in ﬂies could account for DA neurodegeneration in
Drosophila parkin mutants [65].
It is interesting to mention that overexpression of
mutant but not wild-type human parkin in ﬂies also led to
progressive degenerationofDAneuronsfromseveralclusters
accompanied by a progressive motor impairment. These
data suggested a possible dominant mechanism underlying
the pathological phenotypes caused by mutant parkin in
Drosophila, which could directly exert neurotoxicity in vivo
[66, 67].
3.3. PINK1. Mutations in PINK1 are also associated with
recessive Parkinsonism. This gene encodes a putative serine/
threonine kinase with a mitochondrial targeting sequence
[8]. A recent study has demonstrated that the kinase domain
faces to the cytosol, where its physiological substrates may
reside [68]. The Drosophila PINK1 gene encodes a protein
that contains the same domains as its human counterpart,
and ﬂy PINK1 models of PD were generated by transposon-
mediated mutagenesis and RNAi [69–72]. Interestingly,
PINK mutant ﬂies shared marked phenotypic similarities
with parkin mutants. They also exhibited male sterility,
muscle degeneration, hypersensitivity to oxidative stress,
mitochondrial defects, reduced lifespan, and DA neuronal
degeneration accompanied by locomotor defects. Indeed,
genetic analysis demonstrated that PINK1 and parkin are
functionally related. They showed that parkin overexpres-
sion rescued PINK1 mutant phenotypes, whereas PINK1
overexpression had no eﬀect on parkin LOF phenotypes
[69, 70]. These observations suggested that PINK1 and
parkin function in the same pathway, with parkin acting
downstream of PINK1, a n di ts e e m st h a tt h i sp a t h w a yi sc o n -
served between ﬂies and mammals [73]. Several studies have
demonstrated that bothﬂy genesregulate diﬀerentaspects of
mitochondrialphysiology,thusexplainingthemitochondrial
morphological defects observed in Drosophila PINK1 and
parkin mutants. By means of genetic interactions, they illus-
trated a role of the PINK1/Parkin pathway in the regulation
of the mitochondrial remodelling process in the direction of
promoting mitochondrial ﬁssion and/or inhibiting fusion in
Drosophila muscle and neuronal tissues [74–77]. However,
these results also suggested that both genes are not core
componentsofthe mitochondrial dynamics machinery since
LOF of key regulators of this process causes lethality and,
as indicated above, PINK1 and parkin mutants are viable.Parkinson’s Disease 5
Thus, it has been proposed that they probably regulate
additionalaspectsofmitochondrialfunctionthatalsoimpact
mitochondrial morphology [76]. Interestingly, these results
contrast with a human cell-based study which demonstrates
that the PINK1/Parkin pathway promotes mitochondrial
fusion in mammals [78]. One explanation for this discrep-
ancy may be the existence of species-speciﬁc diﬀerences
although the ﬁnal conclusion is that in both systems there
is a disrupted balance between mitochondrial fusion and
ﬁssion [77]. Furthermore, it has been shown that PINK1
directly phosphorylates Parkin to control its translocation to
the mitochondria [78]. Recent studies suggest that Parkin,
together with PINK1, modulates mitochondrial traﬃcking,
especially to the perinuclear region, a subcellular area
associated with autophagy [79] and that PINK1 accumu-
lation on mitochondria is both necessary and suﬃcient
for Parkin recruitment to such organelles. These ﬁndings
provide a biochemical explanation for the genetic epistasis
found betweenPINK1and parkin in Drosophilaand support
a model in which PINK1 signals mitochondrial dysfunction
to Parkin, and Parkin promotes their elimination [79, 80].
Genetic interaction experiments in ﬂies also revealed
putative additional components of the PINK1/Parkin path-
way like Rhomboid-7 and Omi/HtrA2 [81, 82]. It seems
that Rhomboid-7, a mitochondrial protease, could act as
an upstream component of the pathway that may cleave
the mitochondrial target motif of PINK1 thus allowing
its activity not only in the mitochondria but also in the
cytosol [81]. Besides, Omi/HtrA2 was identiﬁed as a possible
regulator of the PINK1/Parkin pathway, acting downstream
of PINK1 in Drosophila [82]. In contrast, another study
showed that Omi/HtrA2 does not play any role in the
PINK1/Parkin pathway [83]. AlthoughOmi/HtrA2 sequence
variations have been associated with an increased risk for PD
[11, 84], its involvement in the disease is still controversial
[12]. Additional work in Drosophila suggested that PINK
deﬁciency also aﬀects synaptic function in neurons, as the
reservepoolofsynapticvesiclesisnotmobilizedduringrapid
stimulation [85].
3.4. DJ-1. Mutations in the DJ-1 gene are associated with
rare familial recessive forms of PD [7]. DJ-1 encodes a highly
conserved protein belonging to the ThiJ/PfPI superfamily of
molecular chaperones [86]. Although originally identiﬁed
as an oncogenic factor [87], DJ-1 is a ubiquitous redox-
responsivecytoprotectiveproteinwith diversefunctionsthat,
particularly in its oxidized form, has been recognized as a
biomarker for cancer and neurodegenerative diseases [88].
Several cysteine residues in the DJ-1 protein can be oxidized
with exposure to oxidative stress agents, being cysteine
106 critically required for DJ-1 to protect against oxidative
damage both in vivo and in vitro [89, 90]. It has been
shown that DJ-1 regulates redox signaling kinase pathways
and acts as a transcriptional regulator of antioxidative gene
batteries[91] ,b u ta l s oa c t sa sar e d o x - s e n s i t i v eR N A - b i n d i n g
protein [92]. In contrast to mammalian species, two DJ-1
orthologs do exist in Drosophila, DJ-1α and DJ-1β.W h i l e
DJ-1α expression is restricted to the male germline, DJ-1β
is ubiquitously expressed as its human counterpart [93, 94].
In order to explore the contribution of DJ-1 in PD patho-
genesis, we and others generated diﬀerent Drosophila PD
models by mutating these genes [50, 53, 93–95]. Those
studies have revealed that ﬂies mutant for DJ-1α, DJ-1β,o r
both are viable but exhibit enhanced sensitivity to toxins
that induce oxidative stress such as H2O2, paraquat or
rotenone, supporting that DJ-1 exerts a protective role
against oxidative stress damage [50, 53, 93–95]. Consistent
with this, we examined DJ-1β mutant ﬂies for the extent of
oxidative damage ﬁnding that DJ-1β loss of function results
in cellular accumulation of reactive oxygen species (ROS)
in adult brains, elevated levels of lipid peroxidation, and
an increased catalase enzymatic activity [54]. It was also
demonstrated that both the aging process and oxidation
challenge promote overoxidation of DJ-1β at cysteine 104
(analogous to cysteine 106 in human DJ-1), a modiﬁcation
that could irreversibly inactivate the protein [90]. Consistent
with this, aged ﬂies showed further vulnerability to oxidative
stress [90]. This suggests that the protective function of DJ-1
against oxidative stress could be progressively lost through
aging, thus increasing the risk of DA neuron loss, since
they are prone to oxidation. Despite this, only two studies
have shown that targeted knockdown of DJ-1α via RNAi
in ﬂies resulted in age-dependent loss of DA neurons in
the DMC [50, 53]. In addition, ﬂies mutant for DJ-1α
and DJ-1β showed reduced lifespan and locomotor defects
[53, 95]. Although initial studies did not examine the DJ-1
mutant ﬂies for mitochondrial pathology that could account
for these phenotypes, a recent analysis has demonstrated
that DJ-1 inactivation leads to mitochondrial dysfunction
in an age-dependent manner not only in ﬂies but also in
mice [96]. Indeed, ﬂies double mutant for DJ-1α and DJ-
1βmanifest additionalphenotypesthatreﬂectmitochondrial
dysfunction such as reduced ATP levels and defects in
spermatogenesis [96].Interestingly,allthesedefectsresemble
those found in parkin and PINK1 mutants (see Sections 3.2
and 3.3). Consistent with this, the study provides evidence
that DJ-1 interacts with the PINK1/Parkin pathway in
Drosophila, and suggests that DJ-1 acts downstream of, or in
parallel to, PINK1 f o rp r o p e rm i t o c h o n d r i a lf u n c t i o n[ 96].
Cell culture studies revealed that a pool of DJ-1 is localized
to the mitochondria [89, 97]. Thus, all these results suggest
that DJ-1, parkin,a n dPINK1 may act in common biological
processes that are critical for mitochondrial function and
that DJ-1 dysfunction may lead to PD pathology through
distinct molecular mechanisms.
3.5. LRRK2. Mutations in LRRK2 are likely the most com-
mon genetic cause of PD and are associated with a dominant
form of the disease [9, 10]. It encodes a large and complex
protein containing several independent domains, including
a GTPase domain and a kinase domain able to exhibit
a GTP-dependent phosphorylation activity [98]. The exact
mechanism by which LRRK2 mutations cause PD is still
unclear. Most disease-associated mutations of LRRK2 have
been shown to increase its kinase activity and thereby its
toxicity, but there is signiﬁcant variation among diﬀerent
mutationswhichcanevenreduceitskinaseactivity orexhibit
a tendency to aggregate [99–101]. In order to understand the6 Parkinson’s Disease
mechanisms of LRRK2-induced pathology, several groups
haveusedDrosophilatomodel LRRK2-linked Parkinsonism.
Expression of either wild-type or mutant forms of human
LRRK2 in ﬂies has led to inconsistent results, especially
regarding neurodegeneration [102–106]. While one group
did not obtain any signiﬁcant defect in the tissues analyzed,
including muscles and DA neurons [102], other studies
reported photoreceptor and/or DA neuron loss by LRRK2
overexpression as well as locomotor impairments [103–106].
Moreover, it was shown that human LRRK2 expression
sensitized ﬂies to environmental toxins such as rotenone
[106]. Interestingly, LRRK2-overexpression phenotypes in
ﬂy eyes and DA neurons were modiﬁed in a complex fashion
by a concomitant expression of PINK1, DJ-1,o rparkin,
suggesting a genetic interaction between these PD-relevant
genes [106]. Regarding this, co-immunoprecipitation assays
performed in cell culture already demonstrated that LRRK2
interacts with Parkin but not with α-Synuclein, DJ-1, or
Tau in human cells [107]. Disparate results have also been
obtained when ablating endogenous LRRK2 expression in
ﬂies [102, 104, 108]. Several studies showed that ﬂies lacking
LRRK2 function showed no changes in DA neuron numbers
and patterns thus indicating that the gene is dispensable
for the survival of DA neurons in this organism [104, 108].
However, one study reported that DA neurons in LRRK2
LOFmutantsshowaseverereductionintyrosinehydroxylase
immunostaining and shrunken morphology, implicating
their degeneration, and exhibit a severely impaired locomo-
tive activity [102]. Diﬀerent results have been also obtained
when exposing those mutants to oxidative stress agents.
While LRRK2 mutants encoding a truncated form of the
protein were selectively sensitive to hydrogen peroxide, but
not to paraquat, rotenone and β-mercaptoethanol [108],
LRRK2 deﬁcient (by transposon insertion or chromosome
deletion), or LRRK2 RNAi animals were shown to be
signiﬁcantly more resistant to hydrogen peroxide-induced
stress [104]. Interestingly, this study also provided genetic
and biochemical evidence that the Drosophila LRRK2 kinase
modulates the maintenance of DA neurons by regulating
protein synthesis, since it can phosphorylate initiation
factor 4E-binding protein (4E-BP), a negative regulator of
eukaryotic protein translation implicated in mediating the
survival response to various physiological stresses [109–
111]. Its phosphorylation relieves its inhibition of protein
translation which could be detrimental when unregulated
in times of stress. This would explain why ﬂies expressing
pathogenic forms of LRRK2 exhibit enhanced sensitivity to
oxidative stress agents while ﬂies lacking LRRK2 activity are
resistant [104]. Consistent with this, it has been recently
demonstrated that LRKK2 interacts with the microRNA
pathway to regulate protein synthesis [112]. It is interesting
to mention that a genetic interaction between 4E-BP (Thor)
and parkin/PINK1 has also been found, because its loss
of function in Drosophila signiﬁcantly reduces parkin and
PINK1 mutants viability while 4E-BP overexpression is
suﬃcient to suppress the phenotypes described in these
mutants [113]. Thus, these results support a general role of
deregulatedprotein translation in PD.Besides, a recent study
has shown that LRRK2also phosphorylates the forkhead box
transcription factor FoxO and enhances its transcriptional
activity, not only in Drosophila but also in humans [114].
They also demonstrated that hid and bim, which encode
two cell death molecules regulated by FoxO, are responsible
for LRRK2-mediated cell death suggesting that they are key
factors during the neurodegeneration in LRRK2-linked PD
[114]. In summary, it seems that the higher kinase activity
exhibited by LRRK2 mutations could cause DA neuron loss
by aﬀecting diﬀerent cellular processes.
4.Using Drosophila Models to Study Molecular
Mechanisms Underlying PD
The main goal of establishing animal models of human
diseases is to provide new insights into their pathogenic
mechanisms. Toaddressthis,Drosophilaoﬀersawidevariety
of genetics tools. One of them is the possibility to perform
geneticscreens,which allowgenome-wideanalysesofgenetic
interactions based on the dominant modiﬁcation of a given
phenotype obtained by loss or gain of function of the gene
of interest. Besides, a candidate gene approach can also be
performed,inwhich onlythosegenesthataresuspectedtobe
related to the PD-linked gene are assayed for modiﬁcations
of the phenotype. Both strategies have allowed identifying
components of multiple signaling pathways involved in PD
pathogenesis. As seen in section 3, some PD-related pheno-
types obtained in the ﬂy models are not externally visible as
is the case of DA neurons loss. Genetic interaction assays
and genetic screens based on such phenotypes are often
unaﬀordable and time consuming. Then, other phenotypes
caused by mutations of the PD-related gene, which are easy
to score and quantify, are used in the assays. Here, we
report several examples of the identiﬁcation of genes and
signaling pathways involved in PD pathogenesis by means
of genetic interaction assays performed in ﬂies (see Table 1).
Similar genetic experiments have been performed to deter-
mine functional relationships among some ofthe PD-related
genes (see Section 3).
In order to identify the molecular mechanisms under-
lying the pathology associated with loss of function of ﬂy
parkin (see Section 3.2), a genetic screen for modiﬁers of
the partial lethality phenotype of Drosophila parkin mutants
was performed. This study identiﬁed an LOF allele of the
glutathione S-transferase S1 (GstS1) gene as the stronger
enhancer of that phenotype [115]. Consistent with this,
it was found that reducing GstS1 activity was able to
enhance DA neuron loss in parkin mutants while GstS1
overexpression signiﬁcantly suppressed that phenotype [62].
Since members of the GST family have been involved in
detoxiﬁcation of ROS [121], these data suggested a con-
nection between parkin and oxidative stress response. This
hypothesis was conﬁrmed when analyzing the transcrip-
tional proﬁle of parkin mutant ﬂies, which showed that an
elevated percentage of deregulated genes in the mutantshave
functions related to oxidative stress response [115].
The importance of glutathione metabolism on DA neu-
ronsurvivalwasalsodemonstratedinaposteriorstudybased
on a candidate gene approach. It showed that LOF mutants
of genes involved in glutathione synthesis (Eip55E and theParkinson’s Disease 7
Table 1:Signalingpathwaysandmolecularprocesses involved in PD pathogenesisthathavebeen identiﬁed by usingDrosophilaPDmodels.
Pathway/process Drosophila model Interacting genes/toxins References
Oxidative stress
parkin GstS1 [62, 115]
Paraquat [58]
α-synuclein
GstS1, Eip55E and Gclm [39]
MsrA/Eip71CD [38]
Sod [40]
DJ-1α/β
Paraquat [53, 90, 93–95]
Rotenone [93]
H2O2 [50, 94]
LRRK2/4E-BP Paraquat, H2O2 [104]
PINK1
Sod [72]
Rotenone [69]
Paraquat [69, 72]
PI3K/Akt signaling DJ-1α/β PTEN, Dp110 [50]
Ras/ERK signaling DJ-1α/β Ret, rl [116]
JNK signaling parkin bsk, hep, puc [59]
DA metabolism Paraquat ple, Pu, Catsup [27]
parkin VMAT [66]
Mitochondrial structure and
function PINK1 parkin [69, 70, 74–76, 78]
TOR signaling parkin/PINK1 4E-BP [82]
Removal of excess or toxic
protein forms
α-synuclein
Hsp70 [117]
ubiquitin [51]
dHDAC6 [118]
SIRT2 [119]
ctsd [120]
parkin PAEL-R [64]
Sept4 [65]
Gcl-modifying subunit, Gclm) or glutathione conjugation
pathways (GstS1) enhanced DA neuron loss of α-Synuclein-
overexpressing ﬂies while their overexpression suppressed
that phenotype. Those genes were previously isolated in
a genetic screen using a yeast model of α-synucleinopathy
[37, 122]. The results obtained in this study indicated that
α-Synuclein toxicity inversely correlates with the abundance
of glutathione and GstS1 and suggest a role for Phase II
detoxiﬁcation pathway in PD pathogenesis [39]. Several
studies have also dealt with the importance of α-Synuclein
oligomers removal from the DA neuron cytoplasm to keep
their integrity. The ﬁnding that progressive loss of DA
neuron integrity produced by α-Synuclein overexpression is
preventable in ﬂies through directed expression of Hsp70
strongly suggested that eliminating toxic forms or excess
of the protein could be central to prevent neuron damage
[117]. Recently,coexpression of ubiquitinhas been shown to
rescue DA neuron degeneration and locomotor dysfunction
in α-Synuclein-overexpressing ﬂies. This neuroprotection
is dependent on the formation of lysine 48 polyubiquitin
linkage which is known to target protein degradation via the
proteasome [51] and suggests that an increase of α-Synuclein
targeting for degradation is able to reduce its toxicity.
The involvement of histone deacetylase 6 (dHDAC6) in
α-Synuclein toxicity was also analyzed [118], due to its
role on sensing ubiquitinated aggregates and consequently
activating chaperones expression, facilitating aggresome for-
mation, and determining the fate of ubiquitinated proteins
[123–125]. The authors found that knocking down the
dHDAC6 gene on α-Synuclein-overexpressing ﬂies increased
the amount of α-Synuclein oligomers while decreased
the number of cytoplasmatic inclusions and DA neurons,
indicating that dHDAC6 protects DA neuron integrity via
promoting α-Synuclein inclusion formation [118]. These
results support the role of LB as a successful defense against
the concentration of toxic protein forms. Interestingly,
inhibition of another protein of the histone deacetylase
family, Sirtuin 2 (SIRT2), was also found to protect against
α-Synuclein toxicity in Drosophila [119]. Finally, another
study reported that deletion of the ctsd gene, which encodes
the lysosomal protease Cathepsin D, promoted the retinal
degeneration observed when in α-Synuclein overexpressing
ﬂies, suggesting that this protease may act as a facilitator of
α-Synuclein-degrading activity [120].8 Parkinson’s Disease
DA neuron degeneration is one of the most distinguish-
ing features of PD. For this reason, it seemed reasonable that
genes involved in cell survival/death could have a role in PD
pathogenesis. One study tackled this question by performing
genetic interaction assays between DJ-1α and candidate
genes or signaling pathways previously implicated in cell
survival. This study led to identify genes in the PI3K/Aktsig-
naling pathway as speciﬁc modiﬁers of the DJ-1α-associated
cell death phenotype. Consistent with the genetic interaction
results, they found that PI3K/Akt signaling regulates cellular
ROS levels and that DJ-1α downregulation leads to PI3K/Akt
signaling impairment. The same eﬀect was observed in
parkin mutants, thus suggesting a common molecular event
between the two models [50]. These results are in contrasts
with those obtained in a recent study that reported no
interaction between DJ-1α/β and PI3K/Akt in the ﬂy eye
[116]. The authors described an interaction between Ret,
a potent activator of both PI3K/Akt and Ras/ERK pathways,
and DJ-1α/β in Drosophila.H o w e v e r ,t h i si n t e r a c t i o ni n
the ﬂy eye seems to be mediated by Ras/ERK [116]. The
discrepancies could be due to the diﬀerent systems used on
each study, although further work would be necessary to
uncover the real connection between DJ-1α/β and PI3K/Akt
signaling. A relationship between parkin and other apoptosis
signaling pathways has also been reported [59, 126]. These
studies showed that parkin LOF mutants exhibit JNK path-
way activation in DA neurons and that downregulation of
this pathway is able to rescue the DA neuron loss phenotype
observedinthesemutants[59].Geneticinteractionsbetween
parkin and members of the JNK pathway also suggested that
parkin is a negative regulator of this pathway and that this
regulation is driven by a reduction in basket transcriptional
levels [59, 126].
Several genetic studies in Drosophila have also shown
that variations in genes regulating dopamine homeostasis,
which are conserved in humans but not known to be
associated with familial PD, can modify the neurodegen-
eration phenotype observed in the PD models and alter
susceptibility to paraquat, a known environmental PD risk
factor [27]. Although it has been extensively discussed, no
agreement on the beneﬁcial/toxic eﬀect of this molecule on
DA neuron survival and consequently on PD patients has
been achieved. Some in vitro studies suggest that treatment
with L-dopamine, the most common palliative pharmaco-
logical compound used in PD patients, could be toxic to
DA neurons due to the activation of oxidative cascades
produced by an increase in dopamine levels [127–129].
Moreover, an elevation of dopamine synthesis in response
to a variety of stressors may expose DA neurons to high
levels of oxidative stress [130–132]. In such a scenario, it
has been shown that hyperactivated dopamine synthesis in
Drosophilacathecolamines up(catsup)m utan ts ,whic hm ight
be expected to place the organism under high levels of
oxidative stress, is instead able to provide protection against
the eﬀects of paraquat exposure. In contrast, compromised
dopamine synthesis enhances susceptibility to paraquat-
induced oxidative stress [27], thus indicating that sensitivity
to paraquat might be modiﬁed by variations in genes that
regulate dopamine synthesis and metabolism. Moreover,
other study has shown that overexpression of the Drosophila
vesicular monoamine transporter (VMAT), which regulates
cytosolic DA homeostasis, partially rescues the degenerative
phenotypes caused by overexpression of human parkin
m u t a n t sw h i l ei t sk n o c k d o w ne x a c e r b a t e st h e s ep h e n o t y p e s
[66]. These result indicate that Parkin-induced neurotoxicity
results from the interaction of mutant human parkin with
cytoplasmic dopamine.
5.Using Drosophila PDModelsto Identify
PotentiallyTherapeuticCompounds
Both the genetic and toxin-induced Drosophila PD models
represent a promising system for therapeutic compound
identiﬁcation. Indeed, during the last decade the eﬀect
of several compounds has been analyzed on behavioural,
neurodegenerative or biochemical phenotypes of such mod-
els leading to the identiﬁcation of potentially therapeutic
compounds that could alleviate PD symptoms (see Table 2).
Although candidate compounds have been always used in
these studies, they open the possibility of performing high
throughput compound screens which will be undoubtedly
useful for ﬁnding new drugs that could alleviate PD symp-
toms.
The ﬁrst published study about compound treatments
in a Drosophila PD model reported the eﬀects of drugs
commonly used for treating PD on the locomotor phe-
notype of α-Synuclein expressing ﬂies and showed that
some of them were able to suppress that phenotype [133].
Subsequently, and given the ability of increased chaperone
activity to counteract α-Synuclein toxicity [117], the eﬀect
of Geldanamycin (GA), an antibiotic able to interfere with
Hsp90 activity and activate stress response, was assayed over
α-Synuclein expressing ﬂies [35, 134]. Notably, feeding these
ﬂies with GA protected DA neurons against α-Synuclein
induced degeneration, and this protection was driven by
an increase in Hsp70 levels [134]. Inhibitors of the histone
deacetylase SIRT2 also showed a protective eﬀect against
α-Synuclein toxicity [119].
Other studies have been also performed in several
Drosophila PD models to look for potentially therapeutic
compounds directed to reduce oxidative stress damage. As
explainedpreviously,thestudyofα-Synucleintoxicityinﬂies
led to the identiﬁcation of Phase II detoxiﬁcation pathway
as a possible target for therapeutic treatment [39]. In fact,
feeding α-Synuclein-expressing ﬂies or Drosophila parkin
mutants with pharmacological inducers of that pathway like
sulforaphane or allyl disulﬁde suppresses the neuronal loss
of both PD models [39]. These ﬁndings raise the possibility
that these and perhaps other chemical inducers of Phase II
detoxiﬁcation pathway may represent potential preventive
agents for PD. Besides, it has been shown that dietary
supplementation with S-methyl-L-cysteine (SMLC) inhibits
the locomotor and circadian rhythm defects caused by
ectopicexpressionofhumanα-SynucleininDrosophila[38].
SMLC participates in the catalytic antioxidant mechanism
involving Methionine sulfoxide reductase A (MSRA), one of
the enzymes that catalyze the oxidation of the amino acid
methionine to methionine sulfoxide, a reversible reactionParkinson’s Disease 9
Table 2: Potentially therapeutic compounds able to modify diﬀerent phenotypes in the Drosophila PD models.
Pathway/process Compound treatment∗ Drosophila model Modiﬁed phenotype/s References
Oxidative stress
Sulforaphane and allyl
disulﬁde
parkin DA neuron number [39]
α-synuclein DA neuron number [39]
S-methyl-L-cysteine α-synuclein Locomotoractivity [38]
Polyphenols α-synuclein Lifespan, locomotor activity [135]
Paraquat and iron Locomotoractivity [136]
α-tocopherol DJ-1β Lifespan [54]
PINK1 Ommatidial degeneration [72]
SOD PINK1 Ommatidial degeneration [72]
Melatonin
DJ-1β Lifespan [54]
Paraquat Locomotor activity [27]
Rotenone Locomotoractivity, DA neuron
number
[27]
Bacopa monieri leaf extract Paraquat Oxidative markers levels [137]
Oxidative
stress/inﬂammatory
process
Minocycline DJ-1α DA neuron number, dopamine
levels
[138]
Celastrol DJ-1α
DA neuron number, dopamine
levels, locomotoractivity, and
survival rate under oxidative
stress conditions
[138]
TOR signaling Rapamycin parkin/PINK1
Thoracic indentations,
locomotor activity, DA neuron
number, and muscle integrity
[82]
Removal of excess or
toxic protein forms Geldanamycin α-synuclein DA neuron number [35, 134]
Zinc homeostasis Zinc chloride parkin
Lifespan, locomotor activity, and
percentage of adulthood
survivors
[139]
∗All treatments were administered as dietary complement.
thathas beenpostulatedtoactprotectingcellsfrom oxidative
damage. Furthermore, grape extract supplementation has
been shown to recover locomotor ability and lifespan in α-
Synuclein-expressing ﬂies. It is known that grape extracts
contain several polyphenols, compounds with antioxidant
properties [135]. Other Drosophila PD models in which
treatments with antioxidant compounds have been shown
to be beneﬁcial are those involving the DJ-1α and DJ-1β
genes [54, 138]. Compounds with antioxidant and anti-
inﬂammatory properties such as celastrol and minocy-
cline conferred potent DA neuroprotection in RNAi DJ-
1α mutants [138]. We have also recently demonstrated that
chronic treatments with antioxidant compounds are able to
modify the lifespan phenotype of DJ-1β mutant ﬂies, thus
suggesting that oxidative stress plays a causal role in such
phenotype [54].
It is known that rapamycin is a small molecule inhibitor
ofTORsignaling thathasbeenshown toleadto4E-BPhypo-
p h o s p h o r y l a t i o ni nv i t r oa n di nv i v o[ 140, 141]. Notably
rapamycin administration wasabletosuppressall pathologic
phenotypes in park and PINK1 mutants. Moreover, this
suppression was found to be 4E-BP-dependent, since the
administration of rapamycin to parkin and Thor or PINK1
and Thor double mutants was completely unable to sup-
press these phenotypes [113]. Since 4E-BP activity can be
manipulatedbysmall moleculeinhibitorssuchasrapamycin,
this pathway represents a viable therapeutic target for PD
treatment. Moreover, it has been recently suggested that
parkin mutants, apart from the described phenotypes, also
present altered zinc homeostasis. This is supported by the
fact that dietary zinc supplementation in the form of zinc
chloride increased lifespan as well as the percentage ofparkin
mutant ﬂies reaching adulthood while this supplemented
diet was deleterious to control ﬂies [139].
Sincemost PD cases are sporadic and could be associated
todiﬀerentenvironmentalagents,itisalsoessentialtheuseof
toxin-induced Drosophila PD models to assay the beneﬁcial
eﬀects of candidate compounds. Polyphenol administration
was also found to exert a beneﬁcial eﬀect on ﬂies exposed
to paraquat and iron, protecting, rescuing, and restoring
the impaired locomotor activity caused by exposure to
those agents [136]. Other antioxidant compounds such as
melatonin have also been found to rescue locomotor deﬁcits
and DA neurodegeneration in ﬂies exposed to rotenone
[26]. Similarly, it has been recently reported that oxidative
perturbations, measured by diﬀerent oxidative markers,10 Parkinson’s Disease
induced by paraquat exposure in Drosophila are mitigated
by treatment with leaf extracts of Bacopa monieri,a nI n d i a n
herb with attributed neuroprotective functions [137].
6.Conclusions
As reported in this review, Drosophila has emerged as
a very valuable model organism to study PD. Although it is
impossible to fully recapitulate the key neuropathologic and
clinical features of human PD in a single model organism,
many of the existing PD models in Drosophila exhibit key
features of the disease and have provided insights into PD
pathogenesis. Either toxin-induced PD models or models
based on mutations in genes that are linked to familial
PD have provided the proper context by which conserved
signaling pathways and molecular processes relevant to the
disease are discovered and compounds able to suppress PD-
related phenotypes in ﬂies are discovered as well. Indeed,
Drosophila PD models represent a promising system for
the identiﬁcation of new genes that could be involved
in PD susceptibility/development as well as of therapeutic
compound that could be relevant to alleviate PD symptoms
in humans.
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